Quince Therapeutics, Inc. — Form 8-K
Filed July 31, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Quince Therapeutics filed an 8-K on July 31, 2026 reporting Item 5.02 (departure of directors/officers and compensatory arrangements). No specific names, departure dates, dollar amounts, equity awards, or compensation details are provided in the filing header or accessible text; the actual substance is contained in the attached iXBRL document which is not legible in this format.
Why this rating
Officer/director changes are routine corporate governance events. Lack of concrete detail prevents assessment of materiality. Relative to $64M market cap, impact depends on seniority and unvested awards—unknown here.
Extracted items
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.